QUOTE AND NEWS
FiercePharma  Sep 19  Comment 
Big Pharma expanded in emerging markets 6.1% last quarter, the biggest jump in more than two years, but GlaxoSmithKline and Eli Lilly didn't reap as much growth as their peers—and all of them may face rising threats ahead.
FierceBiotech  Sep 15  Comment 
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective, prompting unfavorable comparisons with Sanofi and Regeneron's recently approved Dupixent.
FiercePharma  Sep 13  Comment 
LISBON, Portugal—Back in 2015, Boehringer Ingelheim and Eli Lilly were the first drugmakers to show that a diabetes med could cut the risk of cardiovascular death, and they’re still working to capitalize on that advantage.
FiercePharma  Sep 9  Comment 
Thanks to Eli Lilly’s phase 3 top-line announcement in May, industry-watchers knew Cyramza had topped placebo at staving off bladder cancer progression among patients who had progressed through the first line of platinum-based chemo What they...
FiercePharma  Sep 9  Comment 
Eli Lilly is gearing up to challenge Pfizer’s Ibrance and Novartis’ Kisqali in HR-positive, HER2-negative breast cancer, and it rolled out more positive data for candidate abemaciclib over the weekend to help it get there.
FiercePharma  Sep 8  Comment 
Eli Lilly has faced no shortage of trouble in diabetes recently, but the company now faces a new threat from rival Sanofi. The latter company won tentative FDA approval for a biosimilar to Lilly’s Humalog, putting billions in insulin sales at...
MarketWatch  Sep 8  Comment 
Eli Lilly & Co. said early Friday that its migraine prevention drug had positive results in a late-stage, 12-month open-label study. The therapy, galcanezumab, showed a positive safety and tolerability profile in patients, the company said, and...
GenEng News  Sep 7  Comment 
Eli Lilly said this morning it will eliminate 8% of its workforce—approximately 3500 jobs—through a restructuring designed to cut costs and further focus the company on developing new treatments. Lilly said the majority of the 3500 jobs...
Wall Street Journal  Sep 7  Comment 
Eli Lilly plans to cut its global workforce by about 8% and close several facilities, a step it said it needs to make to lower costs and raise investment in new drugs as the company faces patent expirations that will erode sales of older products.
Forbes  Sep 7  Comment 
Venture funds seeded by drug giant Eli Lilly and search behemoth Alphabet are giving $92.7 million to a startup that aims to use machine learning to create personalized treatments for lung and stomach cancer.




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki